Research programme: pegylated therapeutics - Belrose Pharma

Drug Profile

Research programme: pegylated therapeutics - Belrose Pharma

Alternative Names: EZN 3008; PEG C1 esterase inhibitor; Pegylated anti-TNF-α antibody; Pegylated C1 esterase inhibitor; Pegylated interferon-β-1b - Enzon

Latest Information Update: 15 Jul 2013

Price : $50

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Belrose Pharma; Enzon Pharmaceuticals
  • Class Antibodies; Drug conjugates; Interferons; Oligonucleotides; Peptides; Proteins; Small molecules
  • Mechanism of Action Complement C1r inhibitors; Complement C1s inhibitors; Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hereditary angioedema
  • No development reported Autoimmune disorders; Multiple sclerosis

Most Recent Events

  • 15 Jul 2013 Research programme: pegylated therapeutics - Belrose Pharma is available for licensing as of 15 Jul 2013. http://belrosepharma.com/
  • 12 Jul 2013 Preclinical trials in Hereditary angioedema in USA (IV)
  • 12 Jul 2013 Preclinical trials in Hereditary angioedema in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top